Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome

Journal of Clinical Immunology

Volumn 36, Issue 7, 2016, Pages 693-699

  Cattalini, Marco ^a,b   Galli, Jessica ^a   Andreoli, Laura ^a,b   Olivieri, Ivana ^c,d   Ariaudo, Giada ^c,e   Fredi, Micaela ^a   IAGSA study group, ^f   Orcesi, Simona ^c   Tincani, Angela ^a,b   Fazzi, Elisa ^a,b  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f NONE

Author keywords

Aicardi Gouti res syndrome; Auto antibodies; Autoimmunity; Interferonopathy

Indexed keywords

ANTICONVULSIVE AGENT; AUTOANTIBODY; BACLOFEN; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CELL NUCLEUS ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEVOTHYROXINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NUCLEOSOME ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN; PROTEIN TREX1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AICARDI GOUTIERES SYNDROME; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; CHILBLAIN; CHILD; CLINICAL ARTICLE; FAMILY HISTORY; FEMALE; HUMAN; INFANT; MALE; MEDICAL HISTORY; MOUTH ULCER; PRIORITY JOURNAL; SEIZURE; SYMPTOM; ALLELE; BLOOD; COHORT ANALYSIS; DISEASE PREDISPOSITION; GENETIC SCREENING; GENETICS; IMMUNOLOGY; MUTATION; NERVOUS SYSTEM MALFORMATION; NEUROLOGIC DISEASE; NEWBORN; PHENOTYPE; PRESCHOOL CHILD; PROCEDURES;

ALLELES; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; AUTOIMMUNITY; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; GENETIC TESTING; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; NERVOUS SYSTEM MALFORMATIONS; PHENOTYPE;

EID: 84982279598     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-016-0325-y     Document Type: Article

References (26)

1. Dale RC, Tang SP, Heckmatt JZ, Tatnall FM. Familial systemic lupus erythematosus and congenital infection-like syndrome. Neuropediatrics. 2000;31:155–8.
2. Aicardi J, Goutières F. A progressive familial encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol. 1984;15:49–54.
3. Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GM, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167:296–312.
4. Ramantani G, Kohlhase J, Hertzberg C, Innes AM, Engel K, Hunger S, et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. Arthritis Rheum. 2010;62(5):1469–77.
5. Fazzi E, Cattalini M, Orcesi S, Tincani A, Andreoli L, Balottin U, et al. Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? Autoimmun Rev. 2013;12(4):506–9.
6. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and validation of a gross motor function classification system for children with cerebral palsy. Dev Med Child Neurol. 1997;39:214–23.
7. Eliasson AC, Krumlinde-Sundholm L, Rösblad B, Beckung E, Arner M, Ohrvall AM, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol. 2006;48:549–54.
8. Hidecker MJ, Paneth N, Rosenbaum PL, Kent RD, Lillie J, Eulenberg JB, et al. Developing and validating the communication function classification system for individuals with cerebral palsy. Dev Med Child Neurol. 2011;53:704–10.
9. Pincus T, Schur PH, Rose JA, Decker JL, Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Eng J Med. 1969;281:701–5.
10. Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determination—an operative project of the European Antiphospholipid Forum. Thromb Haemost. 2001;86:575–83.
11. Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet. 2007;81(4):713–25.
12. Rice GI, Forte GM, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case–control study. Lancet Neurol. 2013;12(12):1159–69.
13. Crow YJ. Type I, interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91–8.
14. De Laet C, Goyens P, Christophe C, Ferster A, Mascart F, Dan B. Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutieres syndrome. Neuropediatrics. 2005;36:399–402.
15. Rasmussen M, Skullerud K, Bakke SJ, Lebon P, Jahnsen FL. Cerebral thrombotic microangiopaty and antiphospholipid antibodies in Aicardi-Goutieres syndrome—report of two sisters. Neuropediatrics. 2005;36:40–4.
16. Dale RC, Gornall H, Singh-Grewal D, Alcausin M, Rice GI, Crow YJ. Familial Aicardi-Goutieres Syndrome due to SAMHD1 mutations is associated with chronic arthropaty and contractures. Am J Med Genet A. 2010;152A:938–42.
17. Cuadrado E, Vanderver A, Brown KJ, Sandza A, Takanohashi A, Jansen MH, et al. Aicardi-Goutières syndrome harbours abundant systemic and brain-reactive autoantibodies. Ann Rheum Dis. 2015;74(10):1931–9.
18. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C, et al. Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation. Nature. 2015;517(7532):89–93.
19. Olivieri I, Cattalini M, Tonduti D, La Piana R, Uggetti C, Galli J, et al. Dysregulation of the immune system in Aicardi-Goutières syndrome: another example in a TREX1-mutated patient. Lupus. 2013;22(10):1064–9.
20. Biggioggero M, Gabbriellini L, Meroni PL. Type I interferon therapy and its role in autoimmunity. Autoimmunity. 2010;43(3):284–54.
21. Andreoli L, Pregnolato F, Burlingame RW, Allegri F, Rizzini S, Fanelli V, et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? J Autoimm. 2008;30(1–2):51–7.
22. Schmidt JL, Olivieri I, Vento JM, Fazzi E, Gordish-Dressman H, Orcesi S, et al. Family history of autoimmune disease in patients with Aicardi-Goutières syndrome. Clin Dev Immunol. 2012;2012:206730.
23. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39(9):1065–7.
24. Günther C, Kind B, Reijns MA, Berndt N, Martinez-Bueno M, Wolf C, et al. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest. 2015;125(1):413.
25. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–18.
26. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516–20.